Introduction
Ethical dilemmas arise when clinicians are faced with conflicting and mutually exclusive courses of action that create moral uncertainties (Beauchamp and Childress, 2001) . Four ethical principles (respect for patient autonomy [i.e., respect patient's preferences in medical care], beneficence [i.e., act in the best interests of the patient], nonmaleficence [i.e., do no harm; minimize risk to the patient], and justice [i.e., clinical intervention results in fair distribution of clinical benefits and burdens in a population]) form the foundation of modern bioethics (Beauchamp and Childress, 2001) .
In a systematic review of ethical principles in plastic surgery, autonomy was the most common theme (Chung et al., 2009 ). Cosmetic care is considered to be based on an individual's autonomous right to seek to become more beautiful (Nejadsarvari et al., 2016) . A resolution of ethical conflicts often requires prioritizing moral obligations through a process of shared decision making, negotiation, and thoughtful compromise (Mahowald, 2006) .
The aim of this article is to discuss ethical dilemmas related to esthetic procedures during pregnancy on the basis of evidence in support of the safety of such procedures during pregnancy. Ethical principles as applicable to mother and fetus and the concept of the fetus as a patient are discussed. Through the analysis of case scenarios, the article highlights reasons for ethical conflicts related to esthetic procedures during pregnancy, such as a lack of highquality evidence.
Obstetric ethics
Most ethical issues in obstetrics revolve around the maternal-fetal relationship (Digiovanni, 2010) . The interests of the pregnant patient (i.e., autonomy, beneficence, and nonmaleficence) are paramount but must be weighed against the risk to the fetus. This is relevant to performing surgical/cosmetic procedures during pregnancy. The maternal-fetal conflict in this context is between the woman's autonomy and the physician's judgment of what is best for her fetus (Digiovanni, 2010) .
The physician has obligations of beneficence and nonmaleficence to the fetus, which becomes a patient at the age of viability (around 24 weeks' gestation) or when the mother confers this status on her fetus. Patienthood of the fetus can be established by virtue of personhood or its moral status, which is not required to be independent from its mother's status (Chervenak et al., 2007) . Beneficence-based obligations are considered incongruent for the fetus when the procedure increases fetal risks. The approach of the American College of Obstetrics and Gynecology (ACOG) to ethical decision-making is outlined in the Table. Evidence related to the safety of esthetic procedures during pregnancy
The classification of the safety of interventions and medications during pregnancy has generally been based on in vitro mutagenicity studies, laboratory animal studies, and accumulated human experience. There is virtually never a high-quality, prospective, randomized, controlled trial to address fetal safety.
The most minimally invasive cosmetic procedures, such as cryotherapy, shave/punch removal, or electrocautery destruction of benign lesions, are considered safe during pregnancy because they have stood the test of time (Kroumpouzos, 2017; Trivedi et al., 2017) . Procedures performed under local anesthesia, such as those mentioned, are considered safe because of negligible fetal risks associated with the usual volumes of local anesthetic agents. There are no controlled or prospective studies of the aforementioned procedures 
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International Journal of Women's Dermatology during pregnancy. However, in most cases, retrospective series of such procedures have not shown any substantial fetal risks.
Ethical dilemmas related to esthetic procedures during pregnancy
Ethical dilemmas that are relevant to esthetic procedures during pregnancy often arise from a lack of high-quality evidence (arising from randomized controlled trials) with regard to the safety of such procedures. However, health care providers should consider that generating these types of data for esthetic procedures is virtually impossible because of the ethical restrictions on performing relevant studies during gestation.
Does the absence of data from randomized controlled studies always constitute a significant evidential deficit when it comes to ethical decision-making? The question eventually boils down to whether physicians who perform esthetic procedures may, in certain cases, decide to lower the bar with regard to the quality of the data. For example, one may consider accepting the results of a large series that compares adverse fetal outcomes as good evidence when performing an esthetic procedure with background rates in the general population. This may help address ethical dilemmas insofar the evidence is clearly communicated to the pregnant patient; however, some physicians may argue that evaluation of fetal risks with these types of data is not flawless.
Solving ethical dilemmas relevant to esthetic procedures during pregnancy in an evidence-based manner can be challenging, especially because there is neither consensus among experts nor a generally accepted gold standard of quality assessment (Strech, 2008) . The needs and values of the patient should be considered in the ethical decision-making process (ACOG, 2007) , and fact counseling should be nondirective so that patient autonomy is not compromised. The health care provider should weigh the principles underlying each of the arguments made and decide whether one ethical principle has more merit than others in the ethical conflict (e.g., concern for the fetus' well-being [i.e., obligation of beneficence] may come into conflict with respect to the mother's autonomy [ACOG, 2007; ACOG Committee on Ethics, 2009] ). In the case of an esthetic intervention, the ethical obligation of beneficence and nonmaleficence to the fetus should take priority over maternal autonomy. Regardless, physicians are not required to suspend good judgment by acceding to patients' requests for interventions they regard as ill-advised, not medically necessary, or posing even a minimal risk to the fetus.
In addition to principlist ethics based on autonomy, beneficence, and nonmaleficence, there are other ethical theories to consider. Deontological (duty-based) ethics might argue that cosmetic procedures and treatments that are not necessary for the health of the mother are inherently wrong because the mother and physician have a duty to a fetus that is going to be carried to term to take whatever reasonable steps are needed to protect it from even minimal risk of harm.
Furthermore, the fetus is arguably a human life, and its welfare takes precedence over the cosmetic needs of the mother. Virtue ethics deal more with the character of the individual in moral decision-making (i.e., what a virtuous person would do) rather than duties, rules, or ethical principles. From a feminist perspective, a woman should be free to do whatever she desires with her body, but the virtue ethicist would argue that no one, including the physician and pregnant mother, possesses the moral right to engage in what are essentially nontherapeutic (or esthetic) treatments that pose any degree of risk to the fetus.
Informed consent
The informed consent process should include providing information about risks, benefits, and alternatives as they apply to the fetus and pregnant patient (Schwager and Bercovitch, 2013) . Legally and ethically, informed consent requires that the patient be provided with sufficient pertinent information upon which a reasonable patient might make an informed decision, that the patient be free of coercion, and that the patient have sufficient decision-making capacity and comprehension to make a decision with regard to the intervention (Schwager and Bercovitch, 2013) .
Setting realistic expectations before performing cosmetic surgery is an important aspect of the informed consent process (Nejadsarvari et al., 2016) . Disclosure of information should be done by the health care provider in an unbiased, nondirective way. Central to achieving informed consent is the communication between physician and patient. The written consent document should be as thorough as possible (e.g., outline maternal risks and potential fetal risks) but should never be a substitute for the communication involved in the disclosure of information, the conversation that leads to an informed and voluntary consent (ACOG Committee on Ethics, 2009).
In the mutuality of the physician-patient relationship, each is to be respected as a person and supported in the autonomous decisions insofar those decisions are not overridden by other ethical obligations (ACOG Committee on Ethics, 2009). Physicians have a right to conscientious refusal, which refers to the freedom to refuse care to which they may ethically object. This can apply to surgical/cosmetic procedures during pregnancy that may pose significant fetal risks.
Even in this case, health care providers have an ethical obligation to respect the patient's autonomy by providing accurate and unbiased information about her options; taking into account her priorities, values, and preferences; and facilitating appropriate referrals for a second opinion where appropriate (ACOG Committee on Ethics, 2009). However, health care providers have no ethical obligation to refer patients' to a willing health care provider for treatment they consider detrimental to the mother or fetus (ACOG Committee on Ethics, 2013).
Case scenario 1
Jamie is a 27-year-old woman who consults with Dr. M's clinic periodically for esthetic procedures, such as botulinum toxin type A (BTX-A) and filler injections. She works as a spokesperson on television, and her appearance is extremely important to her. She is now 30-weeks pregnant, and the last time she had BTX-A injections was a few weeks before she became pregnant. She has noticed that the esthetic effects of BTX-A have worn off and requests another BTX-A treatment. Dr. M advises against this procedure during pregnancy because the effects on the fetus have not been fully studied.
Tearing up with disappointment, Jamie insists that she has read that BTX-A is now considered safe during pregnancy and that in a large study "there were no significant fetal risks from BTX-A." Jamie insists that her appearance is extremely important for her type of work and would like to have the procedure done. How should Dr. M approach this request?
A) Perform the procedure because that is why the patient came in, and recent data suggest that the procedure is likely safe during pregnancy. B) Send the patient home without performing the procedure, stating that there is no high-quality data about this procedure during pregnancy and he does not want to put the fetus at risk. C) Suggest a different procedure that may yield esthetic improvement, but not as good as with BTX-A. D) Refer the patient to a colleague for a second opinion.
Analysis of case scenario 1
BTX-A likely does not cross the placenta because of its large molecular weight and is not expected to be present in systemic circulation after proper intramuscular or intradermal injection (Tan et al., 2013) . Botulism has been reported in 15 pregnant patients and was not associated with birth defects, neonatal loss, or congenital botulism (Badell et al., 2017) . In two cases of maternal botulism, infant serum was taken, and no botulinum toxin was detected (Tan et al., 2013) .
Most data on BTX-A during pregnancy are derived from retrospective reviews of inadvertent or intentional exposures. A review of case reports/series of BTX-A injections during the first trimester of pregnancy revealed two miscarriages; however, these associations with fetal demise are unclear because both women who miscarried had a history of miscarriage (Kroumpouzos, 2017) . A large Allergan series of BTX-A during pregnancy (232 exposed patients during pregnancy) was published recently and showed rates of spontaneous abortion and fetal defects similar to background rates in the general population (Brin et al., 2016) . These data indicate that BTX-A administration during pregnancy is likely not associated with fetal/neonatal loss and birth defects.
By performing the procedure (Option A), Dr. M respects the patient's autonomous decision; however, the well-being of the fetus takes priority over the cosmetic needs of the mother. The fetus lacks the autonomy to assent to exposure to the drug and must depend on the mother and physician to look after its interests. Based on existing data on BTX-A during pregnancy, the physician may consider that the procedure bears only a very remote risk to the viable fetus and proceed with the procedure. This decision can be ethically challenged, especially because the existing data-although of good quality-cannot serve as a gold standard. Also, the provider should perform thorough fact and risk-benefit counseling prior to obtaining an appropriate informed consent.
Refusing to perform the procedure because of a lack of highquality data and possible fetal risks (Option B) fulfills the principle of nonmaleficence toward the fetus. This is an appropriate ethical choice when the physician appreciates an evidential deficit. However, the health care provider should advise the patient that, although one should keep the bar high with regard to safety data quality, there are no data from randomized controlled trials for esthetic procedures during gestation. Communicating uncertainty should be done in a way that does not diminish patient autonomy (Han, 2013) , and the physician should not attempt to impose his or her own values on the patient (ACOG Committee on Ethics, 2013).
To suggest a different procedure that the physician may consider safer (Option C) is an ethically acceptable option and fulfills the principle of nonmaleficence. However, most alternative esthetic procedures lack controlled data during pregnancy as well and are not as effective as BTX-A for dynamic wrinkle correction. A thorough discussion of the pros and cons of alternative procedures is required, and the patient's autonomy is crucial to the final decision-making.
Finally, a physician who declines to perform a procedure may offer a referral for a second opinion (Option D) because another, likely concordant, opinion may be useful for the patient. This is an ethically appropriate course of action that fulfills the principle of patient autonomy and can be applied when the physician has reservations about performing the procedure during pregnancy and/or the patient cannot reach a decision after thorough, nondirective fact counseling.
Case scenario 2
Niki had several sclerotherapy sessions before her pregnancy. She is now 27 weeks pregnant and more bothered by her spider and reticular leg veins than before. She visits her dermatologist, Dr. Sanson, and requests sclerotherapy treatment even though she is aware that some improvement in her prominent lower limb spider and reticular veins may occur spontaneously postpartum. Dr. Sanson refuses to perform the procedure and advises that it is best to wait until the pressure placed on the pelvic veins during pregnancy is relieved postpartum to have the most effective treatment. Dr. Sanson advises the patient that some sclerosant solutions are known to cross the placenta. Niki is disappointed because she believes that at this stage of her pregnancy, there are no risks for the fetus. She is adamant about having the procedure.
At this point Dr. Sanson should:
A) Perform the procedure because several series have not shown any fetal risks with sclerotherapy during pregnancy. B) Deny the procedure because the fetal risks have not been studied well in the second trimester. C) Recommend conservative measures, such as compression, leg elevation, and lifestyle changes. D) Recommend an alternative esthetic procedure, such as laser treatment, that may be safer during pregnancy.
Analysis of case scenario 2
Varicose, reticular, and spider veins that develop during pregnancy may improve postpartum, and most authors suggest that one should wait at least 6 to 12 months after pregnancy prior to treating the veins (Kroumpouzos, 2017) . According to the German Society of Phlebology, sclerotherapy is absolutely contraindicated during the first trimester of pregnancy and after the 36 th week of gestation, the latter being a period during which the hypercoagulable status of gestation is most pronounced (Pannier and Rabe, 2006; Rabe et al., 2004) . However, a study that compared 45 patients treated with sclerotherapy using sodium tetradecyl sulfate and 56 patients treated conservatively did not show any differences in pregnancy outcomes between the two groups (Abramowitz, 1973) . This was corroborated by a retrospective analysis of case reports and series on sclerotherapy with common sclerosants during undetected pregnancy (Reich-Schupke et al., 2012) . Performing the procedure as requested by the patient (Option A) fulfills the principle of patient autonomy. However, the fetus is viable (fetal patienthood can be established at this gestational age), and fetal risks may exist with sclerotherapy, but there is no absolute contraindication for sclerotherapy during the second trimester of pregnancy. Nevertheless, there are insufficient safety data with regard to sclerotherapy during each trimester of pregnancy with any of the commonly used sclerosants.
Furthermore, pregnancy-induced hypercoagulability, which is most pronounced during the third trimester, is not entirely absent at 27 weeks of gestation. Pregnancy hypercoagulability has been associated with risks such as deep venous thromboembolism (Battinelli et al., 2013; Kroumpouzos and Cohen, 2001 ). The ethically relevant empirical information on sclerotherapy during pregnancy may not reach the status of good evidence. Therefore, it is ethically problematic to choose Option A. By denying the procedure (Option B), Dr. Sanson prioritizes beneficence-nonmaleficence, which is ethically appropriate.
However, denying the procedure may cause patient dissatisfaction if no alternative treatment options are provided. A recommendation of conservative measures (Option C) is both indicated and supported by the literature. This course of action fulfills the ethical principles of beneficence and nonmaleficence. Offering a safer, alternative treatment (Option D) such as longpulsed, Nd:YAG 1064-nm laser may be ethically acceptable; however, such laser treatments are not as effective as sclerotherapy for deeper reticular veins and have adverse effects that patients may be unwilling to risk. An extensive discussion of the risks and benefits of laser treatments should be done, and the risk of post-treatment recurrence before the end of gestation should be emphasized. Based on this scenario, discouraging the patient from laser treatment would be most appropriate course of action.
Conclusions
Ethical dilemmas related to esthetic procedures during pregnancy often reflect a conflict between the woman's autonomy and physician's judgment of what is best for the fetus. The well-being of the fetus and the moral obligation of no harm (beneficence-nonmaleficence) take priority over the cosmetic needs of the mother. Ethical conflicts with regard to cosmetic procedures often arise out of a lack of high-quality evidence and reflect the difficulty of obtaining safety data based on randomized controlled trials during pregnancy. However, as more data become available and more clinical experience accumulates, a broader consensus will likely develop on the safety of various esthetic procedures during pregnancy. 
Patient Page
In addition to the Women's Health Highlight featured article, we have developed a Patient Page which is included as supplemental material of the article. The Patient Page provides essential health information written for patients from experts in the field including easy-to-understand explanations of dermatologic diseases and treatments. This minimizes the risk of misinformation from internet and social media that can cause patient frustration and anxiety. The Patient Page is a concise, informative sheet that the Health Care Provider can download, print and provide to their patients to prompt them to ask relevant questions and begin focused doctor/patient dialog. Click on the supplemental material at the end of the Women's Health Highlight article to view/print the Patient Page.
